

Lucia Trevisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4283/publications.pdf>

Version: 2024-02-01

19
papers

749
citations

623734

14
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

1247
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. <i>Cardiovascular Research</i> , 2022, 118, 988-1003.	3.8	12
2	Targeting of PFKFB3 with miR-206 but not miR-26b inhibits ovarian cancer cell proliferation and migration involving FAK downregulation. <i>FASEB Journal</i> , 2022, 36, e22140.	0.5	9
3	Gender differences and pharmacological regulation of angiogenesis induced by synovial fluids in inflammatory arthritis. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113181.	5.6	9
4	Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. <i>FASEB Journal</i> , 2020, 34, 12768-12784.	0.5	18
5	Sex Differences in the Pro-Angiogenic Response of Human Endothelial Cells: Focus on PFKFB3 and FAK Activation. <i>Frontiers in Pharmacology</i> , 2020, 11, 587221.	3.5	17
6	Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment. <i>Biochemical Pharmacology</i> , 2018, 154, 414-423.	4.4	13
7	Estrogen, Angiogenesis, Immunity and Cell Metabolism: Solving the Puzzle. <i>International Journal of Molecular Sciences</i> , 2018, 19, 859.	4.1	123
8	Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro Polarization?. <i>Frontiers in Pharmacology</i> , 2018, 9, 71.	3.5	180
9	The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 398-407.	2.5	53
10	Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors. <i>British Journal of Pharmacology</i> , 2017, 174, 3094-3106.	5.4	46
11	Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. <i>British Journal of Pharmacology</i> , 2015, 172, 4575-4587.	5.4	16
12	Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. <i>Biochemical Pharmacology</i> , 2014, 89, 197-209.	4.4	72
13	Antiapoptotic and Proliferative Effects of Low Concentrations of 7 β -Hydroxycholesterol in Human Endothelial Cells via ERK Activation. <i>Journal of Vascular Research</i> , 2010, 47, 241-251.	1.4	21
14	Inhibition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) endocytosis by ouabain in human endothelial cells. <i>FEBS Letters</i> , 2006, 580, 2769-2773.	2.8	23
15	Synergism between staurosporine and drugs inducing endoplasmic reticulum stress. <i>Biochemical Pharmacology</i> , 2006, 71, 1562-1569.	4.4	7
16	Effect of vascular endothelial growth factor and epidermal growth factor on iatrogenic apoptosis in human endothelial cells. <i>Biochemical Pharmacology</i> , 2004, 67, 277-284.	4.4	28
17	Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle. <i>Biochemical Pharmacology</i> , 2004, 68, 1331-1338.	4.4	21
18	Antiapoptotic effect of ouabain on human umbilical vein endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 716-721.	2.1	45

#	ARTICLE	IF	CITATIONS
19	Endothelin-1-induced arachidonic acid release by cytosolic phospholipase A2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway. <i>Biochemical Pharmacology</i> , 2002, 64, 425-431.	4.4	36